WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
12,56 USD
arrow_upward
+0,48%(+0,060) 1G
16 ott, 16:00:00 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per WXXWY in corso…
Apertura
12,29 USD
Massimo
12,56 USD
Minimo
12,20 USD
Cap. mercato
198,43 Mld
Vol. medio
61,89K
Volume
110,85K
Max 52 sett.
14,80 USD
Min 52 sett.
7,30 USD
Beta
0,01
Azioni in circolazione
2,06 Mld
N. di dipendenti
15K
Apertura
12,29 USD
Massimo
12,56 USD
Minimo
12,20 USD
Cap. mercato
198,43 Mld
Vol. medio
61,89K
Volume
110,85K
Max 52 sett.
14,80 USD
Min 52 sett.
7,30 USD
Beta
0,01
Azioni in circolazione
2,06 Mld
N. di dipendenti
15K
Articoli giornalistici
Da fonti web e partner giornalistici
MarketScreener Italia
·
11 ore fa
Il Nasdaq chiude in calo e interrompe la serie positiva di quattro settimane a causa delle vendite nel comparto tecnologico
Vietnam.vn
·
1 giorno fa
Lettura rapida 16-10: Il Dow Jones sale di oltre 550 punti mentre i rendimenti obbligazionari calano, PV Power stima un utile di oltre 5.400 miliardi di VND nei primi 9 mesi.
Invezz
·
19 ore fa
Dow apre in rialzo di 240 punti mentre le azioni AI scendono e preoccupa l'inflazione
Borsa Italiana
·
15 ore fa
Borsa: Timido segno meno per il Dow Jones, in calo dello 0,40% alle 19:30
Profilo
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Informazioni su Wuxi Biologics Cayman ADR